Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
about
Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-AnalysisDetermination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status ConsiderationsPharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaThe Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and MetabolismNoninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected miceThe within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVGlobal control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisRedefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Nuclear imaging: a powerful novel approach for tuberculosis.A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patientsRadiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureusIsoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Therapy duration and long-term outcomes in extra-pulmonary tuberculosis.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.The role of delamanid in the treatment of drug-resistant tuberculosis.Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, EthiopiaLow Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometryUrine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept studyAllopatric tuberculosis host-pathogen relationships are associated with greater pulmonary impairmentRadiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase.The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistanceSerum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium DiseaseIsoniazid hair concentrations in children with tuberculosis: a proof of concept studyPharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.Multiplex Assay of Second-Line Anti-Tuberculosis Drugs in Dried Blood Spots Using Ultra-Performance Liquid Chromatography-Tandem Mass SpectrometryThioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.Totally drug-resistant tuberculosis and adjunct therapies.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Pharmacologic considerations in use and development of antituberculosis drugs.Nonclinical models for antituberculosis drug development: a landscape analysis.
P2860
Q26781111-F0516F82-3538-45E9-9512-59E883B47CB6Q27324299-E18DABAB-5376-4D87-9A4F-11719C0BF983Q28079207-B2A2F279-85FB-4931-9866-4DCAD7C6D7D1Q28550488-93FE796F-C3E5-4FB2-94F0-F63473D7C006Q28822540-76A3737C-C704-4E00-AD34-5A2E318B91C3Q30421576-B338B666-19A3-4714-B3D2-6CBE7804CAE1Q33576860-BF2B29F3-EA47-4BF1-A780-570763FF33C8Q33797999-9118A0A6-0212-4369-9474-05D0CFCF1EF8Q33926262-3D91AF2C-85A7-4433-98F8-5BC4BF0E0418Q34298988-721FBC1A-5C36-40B3-B38C-2D4578C82EBDQ34315731-3195FCE7-043B-4F92-AA89-068C77CEA5DCQ34332805-E0FD0392-CB73-4F10-A017-E62F89C0E822Q34622399-CE79DDF0-41DD-4AE5-BB0C-7FAB3A8D151EQ34729493-95C091A5-1A96-409D-8159-D20337369A1CQ35104725-BB28767C-CF61-43E9-A67B-33FD30C311F7Q35167178-37C9488B-BC02-428D-B1C8-F1BDB097E953Q35584822-3BF6A936-2B1C-462E-8C27-EF94DF7657C5Q35624245-9640F6E2-020D-41DD-AE2B-DBDAF1758D7AQ35769140-EB25FE3F-37B0-4124-825D-CC754E6BC12CQ35778303-2535AEC8-AFC2-43B9-A005-B853CC93C540Q35960852-B43C2D6F-39B2-4445-BEB8-F0817AF41ACBQ35960935-45CB0416-9748-4E40-9533-0B0D2E109753Q36036963-7A2C46AE-A054-439B-A77E-FE16D84D344BQ36092035-927D92C2-3315-4EF0-815B-EACA68B84559Q36167169-F08704E2-42F7-4490-90C0-58C261E854DBQ36172383-56B63EDA-7EA0-4608-AE3E-1ECFC933482EQ36439129-08BA7A8E-76B3-43EB-BEEA-794E4870FF7BQ36540893-7E31377A-38A8-4DEE-B5AF-ABCA927389B3Q36730088-8D5F0C8D-1719-420D-9A63-C30893156AE8Q36958417-2AB62957-F78E-419C-92FC-682B6FD99999Q36969720-225A1A93-8CC5-4B46-A114-A623D72A3030Q37084164-BBF6E233-54C4-42BC-9AF4-C3561FF494CCQ37335803-F87AF379-4018-4B4D-B44C-01CF2E5A9521Q37339268-AA8CE5FE-053B-419E-83AD-E53EF754F1AFQ37339290-796E3E42-1F9A-46B8-94CF-B5D09ABEEC88Q38059150-42714FA4-2412-4775-9532-06EA9F3F388DQ38210265-F9C3B602-7FD1-4DC2-9D5D-EE1B6821FDA0Q38213320-834A25FE-45BD-429B-B011-0E09FFA73A52Q38252559-7CDB4C4F-EA21-4237-9A0E-76DDDB3D6BD0Q38502294-564F348A-9DE3-4A2D-A813-64AA10D10D5F
P2860
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@ast
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@en
type
label
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@ast
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@en
prefLabel
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@ast
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@en
P2860
P356
P1476
Meta-analysis of clinical stud ...... e of antituberculosis therapy.
@en
P2093
Jotam G Pasipanodya
P2860
P304
P356
10.1093/CID/CIS353
P407
P577
2012-03-30T00:00:00Z